Building upon the aforementioned concepts, in the present study, we tested 1280 drugs, the majority of which are already approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA), to evaluate their potential to increase DAB2IP levels in prostate cancer cell lines. The gene discussed is DAB2IP; the disease is prostate carcinoma.